Genetics of antipsychotic-induced weight gain: Update and current perspectives

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 2067-2083

  Kao, Amy Cc ^a   Müller, Daniel J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

antipsychotic; genetics; metabolic syndrome; personalized medicine; weight gain

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 3A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; GHRELIN; HISTAMINE H1 RECEPTOR; NEUROLEPTIC AGENT; NUCLEAR FACTOR Y; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SEROTONIN 2C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPONECTIN GENE; AMPK GENE; BDNF GENE; CHM3 GENE; CNR1 GENE; COMT GENE; DBH GENE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FTO GENE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GHRELIN GENE; HISTAMINE H1 RECEPTOR GENE; HUMAN; LEP GENE; LEPR GENE; LIPID METABOLISM; MAO A GENE; MC4R GENE; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; NPY GENE; PPAR GENE; PROTEIN METABOLISM; REVIEW; ROBO1 GENE; SEROTONIN 2C RECEPTOR GENE; SIDE EFFECT; TBC1D1 GENE; TNF ALPHA GENE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEPTIN; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PUBMED; RECEPTOR, SEROTONIN, 5-HT2C; WEIGHT GAIN;

EID: 84889022770     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.207     Document Type: Review

References (132)

1. Liou YJ, Bai YM, Lin E et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J. 12(1), 54-61 (2012).
2. Lee AK, Bishop JR. Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics 12(7), 999-1016 (2011).
3. Lipsy RJ. The National Cholesterol Education Program Adult Treatment Panel III guidelines. J. Manag. Care Pharm. 9(1 Suppl.), S2-S5 (2003).
4. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J. Clin. Psychiatry 65(Suppl. 18), S13-S26 (2004).
5. Mas S, Llerena A, Saiz J, Bernardo M, Lafuente A. Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. Pharmacogenomics 13(15), 1773-1782 (2012).
6. Madras BK. History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J. Hist. Neurosci. 22(1), 62-78 (2013).
7. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 17(3), 242-266 (2012).
8. Müller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7(6), 863-887 (2006).
9. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry 158(3), 360-369 (2001).
10. Risselada AJ, Mulder H, Heerdink ER, Egberts TC. Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics 12(8), 1213-1227 (2011).
11. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol. Ther. 125(1), 169-179 (2010).
12. Gebhardt S, Theisen FM, Haberhausen M et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J. Clin. Pharm. Ther. 35(2), 207-211 (2010).
13. Travis MJ, Busatto GF, Pilowsky LS et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br. J. Psychiatry: J. Ment. Sci. 173, 236-241 (1998).
14. Müller DJ, Muglia P, Fortune T, Kennedy JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol. Res. 49(4), 309-329 (2004).
15. Reynolds GP. Pharmacogenetic aspects of antipsychotic drug-induced weight gain-a critical review. Clin. Psychopharmacol. Neurosci. 10(2), 71-77 (2012).
16. Vauquelin G, Bostoen S, Vanderheyden P, Seeman P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch. Pharmacol. 385(4), 337-372 (2012).
17. Müller DJ, Zai CC, Sicard M et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics 12(2), 156-164 (2012).
18. De Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology 225(1), 1-19 (2013).
19. Wallace TJ, Zai CC, Brandl EJ, Muller DJ. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmacogenomics Pers. Med. 4, 83-93 (2011).
20. Houston JP, Kohler J, Bishop JR et al. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J. Clin. Psychiatry 73(8), 1077-1086 (2012).
21. Giegling I, Balzarro B, Porcelli S et al. Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. Eur. Arch. Psychiatry Clin. Neurosci. 263(1), 65-74 (2013).
22. Duan J, Wainwright MS, Comeron JM et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12(3), 205-216 (2003).
23. Hirvonen MM, Laakso A, Nagren K, Rinne JO, Pohjalainen T, Hietala J. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63(10), 907-912 (2009).
24. Sicard MN, Zai CC, Tiwari AK et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 11(11), 1561-1571 (2010).
25. Wu R, Zhao J, Shao P, Ou J, Chang M. Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36(8), 720-723 (2011).
26. Gregoor JG, van der Weide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics 12(6), 919-923 (2011).
27. Kang SH, Lee JI, Chang AK, Joo YH, Kim CY, Kim SY. Genetic polymorphisms in the HTR2C and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients with schizophrenia taking clozapine. Psychiatry Investig. 8(3), 262-268 (2011).
28. Risselada AJ, Vehof J, Bruggeman R et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J. 12(1), 62-67 (2012).
29. Mulder H, Cohen D, Scheffer H et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol. 29(1), 16-20 (2009).
30. Mulder H, Franke B, van der-Beek van der AA et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J. Clin. Psychopharmacol. 27(4), 338-343 (2007).
31. Hill MJ, Reynolds GP. 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res. 1149, 14-17 (2007).
32. Hill MJ, Reynolds GP. Functional consequences of two HTR2C polymorphisms associated with antipsychotic-induced weight gain. Pharmacogenomics 12(5), 727-734 (2011).
33. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J et al. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics J. 13(2), 197-204 (2013).
34. Luca VD, Souza RP, Viggiano E et al. Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. Hum. Psychopharmacol. 26(6), 386-391 (2011).
35. Sasayama D, Hori H, Teraishi T et al. Possible impact of ADRB3 Trp64Arg polymorphism on BMI in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 38(2), 341-344 (2012).
36. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol. Ther. 135(2), 113-122 (2012).
37. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatry 62(Suppl. 23), S45-S66 (2001).
38. Ujike H, Nomura A, Morita Y et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J. Clin. Psychiatry 69(9), 1416-1422 (2008).
39. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS ONE 6(8), e22662 (2011).
40. Jassim G, Skrede S, Vazquez MJ et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl.) 219(3), 783-794 (2012).
41. Tulipano G, Rizzetti C, Bianchi I, Fanzani A, Spano P, Cocchi D. Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation. Neuroendocrinology 85(2), 61-70 (2007).
42. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32(4), 765-772 (2007).
43. Fontanesi L, Bertolini F. The TBC1D1 gene: structure, function, and association with obesity and related traits. Vitam. Horm. 91, 77-95 (2013).
44. Jessen N, An D, Lihn AS et al. Exercise increases TBC1D1 phosphorylation in human skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 301(1), E164-E171 (2011).
45. Szekeres F, Chadt A, Tom RZ et al. The Rab-GTPase-activating protein TBC1D1 regulates skeletal muscle glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 303(4), E524-E533 (2012).
46. Chadt A, Leicht K, Deshmukh A et al. Tbc1d1 mutation in lean mouse strain confers leanness and protects from diet-induced obesity. Nat. Genet. 40(11), 1354-1359 (2008).
47. Meyre D, Farge M, Lecoeur C et al. R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population. Hum. Mol. Genet. 17(12), 1798-1802 (2008).
48. Stone S, Abkevich V, Russell DL et al. TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. Hum. Mol. Genet. 15(18), 2709-2720 (2006).
49. Kim JH, Lee JO, Lee SK et al. Clozapine activates AMP-activated protein kinase (AMPK) in C2C12 myotube cells and stimulates glucose uptake. Life Sci. 87(1-2), 42-48 (2010).
50. Brandl EJ, Tiwari AK, Lett TA et al. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Hum. Psychopharmacol. 28(2), 183-187 (2013).
51. Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology 220(1), 225-241 (2012).
52. Vehof J, Risselada AJ, Al Hadithy AF et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology 216(2), 257-265 (2011).
53. Weston-Green K, Huang XF, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur. Neuropsychopharmacol. 22(5), 364-373 (2012).
54. Gautam D, Han SJ, Hamdan FF et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 3(6), 449-461 (2006).
55. Fuso A. The 'golden age' of DNA methylation in neurodegenerative diseases. Clin. Chem. Lab. Med. 51(3), 523-534 (2012).
56. Yager JD. Catechol-methyltransferase: characteristics, polymorphisms and role in breast cancer. Drug Discov. Today Dis. Mech. 9(1-2), e41-e46 (2012).
57. Garcia-Miss Mdel R, Perez-Mutul J, Lopez-Canul B et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J. Psychiatr. Res. 44(7), 441-446 (2010).
58. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr. Res. 98(1-3), 47-54 (2008).
59. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr. Res. 121(1-3), 193-198 (2010).
60. Kopeckova M, Paclt I, Goetz P. Polymorphisms and low plasma activity of dopamine-beta-hydroxylase in ADHD children. Neuro Endocrinol. Lett. 27(6), 748-754 (2006).
61. Gong P, Xi S, Shen G et al. The effects of DBH, MAOA, and MAOB on attentional biases for facial expressions. J. Mol. Neurosci. 49(3), 606-613 (2013).
62. Cohen-Woods S, Craig IW, McGuffin P. The current state of play on the molecular genetics of depression. Psychol. Med. 43(4), 673-687 (2013).
63. Pizzinat N, Girolami JP, Parini A, Pecher C, Ordener C. Serotonin metabolism in rat mesangial cells: involvement of a serotonin transporter and monoamine oxidase A. Kidney Int. 56(4), 1391-1399 (1999).
64. Bray NJ, Buckland PR, Williams NM et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 73(1), 152-161 (2003).
65. Bassett AS, Caluseriu O, Weksberg R, Young DA, Chow EW. Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol. Psychiatry 61(10), 1135-1140 (2007).
66. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. FEBS 223(3), 1049-1059 (1994).
67. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17(12), 1206-1227 (2012).
68. Kuzman MR, Müller DJ. Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. Pharmacogenomics 13(8), 843-846 (2012).
69. Ellingrod VL, Taylor SF, Dalack G et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J. Clin. Psychopharmacol. 32(2), 261-265 (2012).
70. Devlin AM, Ngai YF, Ronsley R, Panagiotopoulos C. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl. Psychiatry 2, e71 (2012).
71. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 407(6806), 908-913 (2000).
72. Stark R, Ashley SE, Andrews ZB. AMPK and the neuroendocrine regulation of appetite and energy expenditure. Mol. Cell. Endocrinol. 366(2), 215-223 (2013).
73. Tsai MC, Chang CM, Liu CY, Chang PY, Huang TL. Association of serum levels of leptin, ghrelin, and adiponectin in schizophrenic patients and healthy controls. Int. J. Psychiatry Clin. Pract. 15(2), 106-111 (2011).
74. Santini F, Maffei M, Pelosini C, Salvetti G, Scartabelli G, Pinchera A. Melanocortin-4 receptor mutations in obesity. Adv. Clin. Chem. 48, 95-109 (2009).
75. Mason BL, Lobo MK, Parada LF, Lutter M. Trk B signaling in dopamine 1 receptor neurons regulates food intake and body weight. Obesity (Silver Spring) doi:10.1002/oby.20382 (2013) (Epub ahead of print).
76. Zai GC, Zai CC, Chowdhury NI et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 39(1), 96-101 (2012).
77. Souza RP, Tiwari AK, Chowdhury NI et al. Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. J. Psychiatr. Res. 46(4), 462-468 (2012).
78. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl Acad. Sci. USA 104(9), 3456-3459 (2007).
79. Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr. Res. 100(1-3), 70-85 (2008).
80. Yang Y, Li W, Zhao J et al. Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients. Behav. Brain Funct. 8, 11 (2012).
81. Farooqi IS, O'Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nat. Clin. Pract. Endocrinol. Metab. 4(10), 569-577 (2008).
82. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505), 425-432 (1994).
83. Millan MA, Jacobowitz DM, Hauger RL, Catt KJ, Aguilera G. Distribution of corticotropin-releasing factor receptors in primate brain. Proc. Natl Acad. Sci. USA 83(6), 1921-1925 (1986).
84. Brandl EJ, Frydrychowicz C, Tiwari AK et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 38(2), 134-141 (2012).
85. Furusawa T, Naka I, Yamauchi T et al. The Q223R polymorphism in LEPR is associated with obesity in Pacific islanders. Hum. Genet. 127(3), 287-294 (2010).
86. Tiwari AK, Brandl EJ, Weber C et al. Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. J. Clin. Psychopharmacol. 33(1), 11-17 (2013).
87. Srisai D, Gillum MP, Panaro BL et al. Characterization of the hyperphagic response to dietary fat in the MC4R knockout mouse. Endocrinology 152(3), 890-902 (2011).
88. Malhotra AK, Correll CU, Chowdhury NI et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch. Gen. Psychiatry 69(9), 904-912 (2012).
89. Chowdhury NI, Tiwari AK, Souza RP et al. Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J. 13(3), 272-279 (2012).
90. Czerwensky F, Leucht S, Steimer W. Association of the common MC4R rs17782313 polymorphism with antipsychotic-related weight gain. J. Clin. Psychopharmacol. 33(1), 74-79 (2013).
91. Pelleymounter MA, Cullen MJ, Wellman CL. Characteristics of BDNF-induced weight loss. Exp. Neurol. 131(2), 229-238 (1995).
92. Lee JG, Cho HY, Park SW, Seo MK, Kim YH. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(6), 1001-1006 (2010).
93. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25(11), 933-969 (2011).
94. Tsai A, Liou YJ, Hong CJ, Wu CL, Tsai SJ, Bai YM. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. Neuromol. Med. 13(4), 328-333 (2011).
95. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 35(3), 528-548 (2009).
96. Poelmans G, Buitelaar JK, Pauls DL, Franke B. A theoretical molecular network for dyslexia: integrating available genetic findings. Mol. Psychiatry 16(4), 365-382 (2011).
97. Ganella DE, Ryan PJ, Bathgate RA, Gundlach AL. Increased feeding and body weight gain in rats after acute and chronic activation of RXFP3 by relaxin-3 and receptor-selective peptides: functional and therapeutic implications. Behav. Pharmacol. 23(5-6), 516-525 (2012).
98. Müller DJ, Chowdhury NI, Zai CC. The pharmacogenetics of antipsychotic-induced adverse events. Curr. Opin. Psychiatry 26(2), 144-150 (2013).
99. Pollmacher T, Schuld A, Kraus T, Haack M, Hinze-Selch D. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr. Neurol. Psychiatr. 69(Suppl. 2), S65-S74 (2001).
100. Berthold-Losleben M, Heitmann S, Himmerich H. Anti-inflammatory drugs in psychiatry. Inflamm. Allergy Drug Targets 8(4), 266-276 (2009).
101. Vehof J, Al Hadithy AF, Burger H et al. Association between the ROBO1 gene and body mass index in patients using antipsychotics. Psychiatr. Genet. 21(4), 202-207 (2011).
102. Lasky-Su J, Lyon HN, Emilsson V et al. On the replication of genetic associations: timing can be everything! Am. J. Hum. Genet. 82(4), 849-858 (2008).
103. Callander GE, Bathgate RA. Relaxin family peptide systems and the central nervous system. Cell. Mol. Life Sci. 67(14), 2327-2341 (2010).
104. Munro J, Skrobot O, Sanyoura M et al. Relaxin polymorphisms associated with metabolic disturbance in patients treated with antipsychotics. J. Psychopharmacol. 26(3), 374-379 (2012).
105. Huang HH, Wang YC, Wu CL et al. TNF-alpha-308 GA polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment. Neurosci. Lett. 504(3), 277-280 (2011).
106. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091), 87-91 (1993).
107. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95(5), 2409-2415 (1995).
108. Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr. Res. 43(2-3), 164-166 (2000).
109. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ. Genetic association between TNF-alpha-308 GA polymorphism and longitudinal weight change during clozapine treatment. Hum. Psychopharmacol. 25(4), 303-309 (2010).
110. Yang Z, Yin JY, Gong ZC et al. Evidence for an effect of clozapine on the regulation of fat-cell derived factors. Clin. Chim. Acta 408(1-2), 98-104 (2009).
111. Chen VC, Wang TN, Lu ML et al. Weight gain and ghrelin level after olanzapine monotherapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(2), 632-635 (2011).
112. Smith EM, Zhang Y, Baye TM et al. INSIG1 influences obesity-related hypertriglyceridemia in humans. J. Lipid Res. 51(4), 701-708 (2010).
113. Jo Y, Lee PC, Sguigna PV, Debose-Boyd RA. Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8. Proc. Natl Acad. Sci. USA 108(51), 20503-20508 (2011).
114. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13(4), 251-262 (2012).
115. Staeker J, Leucht S, Steimer W. Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. Mol. Diagn. Ther. 16(2), 93-98 (2012).
116. Fernandez E, Carrizo E, Connell L, Baptista T. Pro12Ala polymorphism of the PPAR-gamma 2 gene, metabolic syndrome and response to metformin in clozapine-treated patients. Schizophr. Res. 137(1-3), 262-263 (2012).
117. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor gamma C161-T polymorphism and coronary artery disease. Cardiovasc. Res. 44(3), 588-594 (1999).
118. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7(8), 941-946 (2001).
119. Jassim G, Ferno J, Theisen FM et al. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry 44(1), 15-20 (2011).
120. Scuteri A, Sanna S, Chen WM et al. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 3(7), e115 (2007).
121. Dina C, Meyre D, Gallina S et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 39(6), 724-726 (2007).
122. Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316(5826), 889-894 (2007).
123. Fawcett KA, Barroso I. The genetics of obesity: FTO leads the way. Trends Genet. 26(6), 266-274 (2010).
124. Reynolds GP, Yevtushenko OO, Gordon S, Arranz B, San L, Cooper SJ. The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients. Int. J. Neuropsychopharmacol. 16(6), 1421-1425 (2013).
125. Herbert A, Gerry NP, McQueen MB et al. A common genetic variant is associated with adult and childhood obesity. Science 312(5771), 279-283 (2006).
126. Le Hellard S, Theisen FM, Haberhausen M et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol. Psychiatry 14(3), 308-317 (2009).
127. Lan TH, Loh EW, Wu MS et al. Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics. Mol. Psychiatry 13(12), 1129-1137 (2008).
128. Nurmi EL, Spilman SL, Whelan F et al. Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies. Transl. Psychiatry 3, e274 (2013).
129. Hall-Flavin DK, Winner JG, Allen JD et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry 2, e172 (2012).
130. Guest PC, Martins-De-Souza D, Schwarz E et al. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Med. 5(3), 25 (2013).
131. Papanastasiou E. Interventions for the metabolic syndrome in schizophrenia: a review. Ther. Adv. Endocrinol. Metab. 3(5), 141-162 (2012).
132. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr. Res. 140(1-3), 159-168 (2012).